In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Protected dosing routine. Further members will probably be enrolled with the discovered monotherapy dosign program. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 are going to be offered as "include-on" therapy. In https://abbv-744brd4inhibitormech91345.iyublog.com/31400200/5-essential-elements-for-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc